Anti-Infective Vaccines Market

Anti-Infective Vaccines Market Overview (2022 to 2032)

The global anti-infective vaccines market was valued at around USD 51.0 Billion at the end of 2021. The market is projected to register a 12.3% CAGR and top a valuation of USD 168.7 Billion by 2032.

The anti-infective vaccines market will grow substantially as the epidemiological burden of infectious diseases increases worldwide.

Vaccines function by exposing the immune system to disease-causing pathogens (bacteria or viruses) that are dead or weak, vaccines help lower the risk of certain illnesses and infections. This process increases the development of antibodies, which can offer immunity against one or more diseases and infections.

Depending on the immune system's reaction to the vaccine introduction and the needs of the target patient. There are many different types of vaccines for different applications for treating infections such as bacterial/viral infection and influenza, including inactivated vaccines, live/attenuated vaccines, and conjugate vaccines.

Attributes	Details
Anti-Infective Vaccines Market Value in 2021	USD 51.0 Billion
Anti-Infective Vaccines Market Value in 2032	USD 168.7 Billion
Anti-Infective Vaccines Market CAGR (2022 to 2032)	12.3%

What are the Major Drivers Boosting the Demand for Anti-Infective Vaccines Market?

A growing population at risk for various infections, the advent of antibiotic-resistant pathogenic organisms, and the ongoing discovery of novel pathogens all constitute a significant challenge to public health. Given the clear and rising risk of pandemic disease and the risk of infection, the development of vaccinations that optimize protective immunity against such organisms constitutes an urgent need for anti-infective vaccine research. Over the forecast period, all of these variables are anticipated to fuel the market expansion for anti-infective vaccines.

The prevalence of infectious diseases strains society socially and financially. For instance, each year, millions of individuals are affected by influenza, which lowers productivity and causes financial losses. Governments are now recognizing the severity of influenza as a serious illness that increases healthcare costs and places a financial strain on the government.

Furthermore, the same is true for the different infectious diseases that can be prevented with vaccination, including meningitis, pneumococcal disease, and infectious disorders like hepatitis, meningitis, and pneumococcus. Governments are aiming to broaden their vaccination programs in order to increase immunization coverage rates among the population who are the backbone of the economy. In the future, the anti-infective vaccines market is anticipated to be influenced by the aforementioned considerations.

Which Region Shows Strong Growth Potential in the Anti-Infective Vaccines Market?

The anti-infective vaccines market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.

North America is the leading region in the global anti-infective vaccines market owing to better awareness among people about health care and the advanced treatment options for the treatment of a number of infections region.

Apart from North America, the European anti-infective vaccines market is also expected to display lucrative growth in the projected years because of the presence of major players in the industry

The East Asian region is predicted to show lucrative growth owing to the growing geriatric population and rising prevalence of infections.

Who are the Key Players in the Anti-Infective Vaccines Market?

Sanofi Pasteur, Merck & Co., MedImmune LLC, Novartis Vaccines, Diagnostics Ltd., Intercell Biomedical, MassBiologics, Barr Labs, Inc., Organon Teknika Co., Emergent BioDefense Operations Lansing Inc., CSL Ltd., ID Biomedical Co., Protein Sciences Co.

Scope of Report

Report Attributes	Details
Growth Rate	CAGR of 12.3% from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2012 to 2021
Forecast Period	2022 to 2032
Qualitative Units	Revenue in USD Billion, Volume in Units, and CAGR from 2022 to 2032
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segment Covered	Type, Application, Distribution Channel, Region
Region Covered	North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa
Key Countries Profiled	USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Players	Sanofi Pasteur; Merck & Co.; MedImmune LLC; Novartis Vaccines; Diagnostics Ltd.; Intercell Biomedical; MassBiologics; Barr Labs, Inc.; Organon Teknika Co.; Emergent BioDefense Operations Lansing Inc.; CSL Ltd.; ID Biomedical Co.; Protein Sciences Co.
Customization	Available Upon Request

Table of Content

• 1. Executive Summary
• 2. Industry Introduction, including Taxonomy and Market Definition
• 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
• 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections
• 5. Pricing Analysis
• 6. Global Market Analysis and Forecast
  • 6.1. Type
  • 6.2. Application
  • 6.3. Distribution Channel
• 7. Global Market Analysis and Forecast, By Type
  • 7.1. Inactivated Vaccines
  • 7.2. Conjugate Vaccines
  • 7.3. Live/Attenuated Vaccines
  • 7.4. Others
• 8. Global Market Analysis and Forecast, By Application
  • 8.1. Bacterial Diseases
  • 8.2. Viral Diseases
  • 8.3. Others
• 9. Global Market Analysis and Forecast, By Distribution Channel
  • 9.1. Hospital Pharmacies
  • 9.2. Retail Pharmacies
  • 9.3. Others
• 10. Global Market Analysis and Forecast, By Region
  • 10.1. North America
  • 10.2. Latin America
  • 10.3. Europe
  • 10.4. East Asia
  • 10.5. South Asia & Pacific
  • 10.6. The Middle East and Africa (MEA)
• 11. North America Sales Analysis and Forecast, by Key Segments and Countries
• 12. Latin America Sales Analysis and Forecast, by Key Segments and Countries
• 13. Europe Sales Analysis and Forecast, by Key Segments and Countries
• 14. East Asia Sales Analysis and Forecast, by Key Segments and Countries
• 15. South Asia & Pacific Sales Analysis and Forecast, by Key Segments and Countries
• 16. The Middle East and Africa (MEA) Sales Analysis and Forecast, by Key Segments and Countries
• 17. Sales Forecast by Type, Application, and Distribution Channel for 30 Countries
• 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
• 19. Company Profile
  • 19.1. Sanofi Pasteur
  • 19.2. Merck & Co.
  • 19.3. MedImmune LLC
  • 19.4. Novartis Vaccines
  • 19.5. Diagnostics Ltd.
  • 19.6. Intercell Biomedical
  • 19.7. MassBiologics
  • 19.8. Barr Labs, Inc.
  • 19.9. Organon Teknika Co.
  • 19.10. Emergent BioDefense Operations Lansing Inc.
  • 19.11. CSL Ltd.
  • 19.12. ID Biomedical Co.
  • 19.13. Protein Sciences Co.